Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRCP | P42785 | 3/20 | 0.62 |
| ▸ | HTR2C | P28335 | 5/20 | 0.47 |
| ▸ | HTR2B | P41595 | 2/20 | 0.47 |
| ▸ | CCNK | O75909 | 1/20 | 0.43 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.43 |
| ▸ | TLR2 | O60603 | 2/20 | 0.42 |
| ▸ | TERT | O14746 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.41 |
| ▸ | NOS2 | P35228 | 2/20 | 0.41 |
| ▸ | NOS3 | P29474 | 1/20 | 0.41 |
| ▸ | NOS1 | P29475 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7067527 | 1.00 | PRCP (0.62) | PRCPHTR2CHTR2BCCNKCDK12 | |
| SCHEMBL12990763 | 1.00 | PRCP (0.62) | PRCPHTR2CHTR2BCCNKCDK12 | |
| SCHEMBL5498791 | 0.90 | PRCP (0.68) | PRCPHTR2CHTR2BCCNKCDK12 | |
| SCHEMBL8548319 | 0.90 | PRCP (0.68) | PRCPHTR2CHTR2BCCNKCDK12 | |
| SCHEMBL15329272 | 0.89 | PRCP (0.70) | PRCPHTR2CHTR2BCCNKCDK12 | |
| SCHEMBL943040 | 0.87 | PRCP (0.58) | PRCPHTR2CHTR2BTLR2TERT | |
| SCHEMBL10978548 | 0.87 | PRCP (0.73) | PRCPHTR2CHTR2BTLR2DPP7 | |
| SCHEMBL5097625 | 0.84 | PRCP (0.64) | PRCPHTR2CHTR2BCCNKCDK12 | |
| SCHEMBL21582234 | 0.84 | PRCP (0.64) | PRCPHTR2CHTR2BCCNKCDK12 | |
| SCHEMBL4578350 | 0.84 | PRCP (0.64) | PRCPHTR2CHTR2BCCNKCDK12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1100816-B1 | AEROTHRICIN ANALOGS, THEIR PREPARATION AND USE | BASILEA PHARMACEUTICA AG (CH) | 2007-08-08 | — | — | EP | disclosed |
| EP-1251827-B1 | NASALLY ADMINISTRABLE ANTIFUNGAL CYCLIC PEPTIDE COMPOSITIONS | BASILEA PHARMACEUTICA AG (CH) | 2004-05-26 | — | — | EP | disclosed |
| US-6489440-B1 | Cyclic compounds | BASILEA PHARMACEUTICA AG (CH) | 2002-12-03 | — | — | US | disclosed |
| EP-1251827-A2 | NASALLY ADMINISTRABLE CYCLIC PEPTIDE COMPOSITIONS | Basilea Pharmaceutica AG (CH) | 2002-10-30 | — | — | EP | disclosed |
| US-20010038824-A1 | Intranasal cyclic peptide formulations | BASILEA PHARMACEUTICA AG (CH) | 2001-11-08 | — | — | US | disclosed |
| WO-2001052894-A2 | NASALLY ADMINISTRABLE CYCLIC PEPTIDE COMPOSITIONS | BASILEA PHARMACEUTICA AG (CH) | 2001-07-26 | — | — | WO | disclosed |
| EP-1100816-A1 | AEROTHRICIN ANALOGS, THEIR PREPARATION AND USE | F. HOFFMANN-LA ROCHE AG (CH) | 2001-05-23 | — | — | EP | disclosed |
| WO-2000005251-A1 | AEROTHRICIN ANALOGS, THEIR PREPARATION AND USE | F. HOFFMANN-LA ROCHE AG (CH) | 2000-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010038824-A1 | Intranasal cyclic peptide formulations | VIP, NPPA, SSTR5 | PRCP 199/4885HTR2C 4197/4885HTR2B 3401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.